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Key Points
• Pembrolizumab treat-
ment of melanoma and
concomitant sAML
resulted in a significant
platelet response and
clearance of IDH1
mutation.
• Pembrolizumab therapy
and response was
associated with an
increased PD-L1
expression on acute
myeloid leukemia blasts
and T cells.
Introduction
Cancer cells use the interaction between immune-checkpoint receptor programmed cell death
protein 1 (PD-1) on activated T cells and programmed cell death ligand 1 (PD-L1) on tumor cells and
various cell types of the tumor microenvironment to evade immune surveillance.1,2 Blocking the
interaction between PD-1 and PD-L1 with checkpoint inhibitors can improve T-cell reactions and
mediate efficient antitumor activity in a variety of solid tumors including melanoma.3,4 However,
clinical data from patients with myeloid diseases that are treated with these agents are limited to
clinical trials in advanced disease.5 Pembrolizumab (PEM) is a humanized monoclonal antibody of the
immunoglobulin G4/k isotype designed to block PD-1/PD-L1 interactions and is approved for
various solid tumors including advanced melanoma.6
Case description
Here, we describe a patient with advanced mucosal melanoma and concomitant acute myeloid
leukemia (AML), who was treated with single-agent PEM as first-line therapy. The 80-year-old
patient presented initially with myelodysplastic syndrome (MDS) including transfusion-dependent
anemia, neutropenia, and thrombocytopenia. MDS was type EB-1 (World Health Organization
2016) and displayed normal cytogenetics. Next-generation sequencing detected IDH1, IDH2,
ASXL1, RUNX1, and STAG2 mutations (Figure 1A). Less than 3 months later, the patient was
diagnosed with PD-L1-negative anorectal melanoma with satellite metastases. Because of
progressive thrombocytopenia and neutropenia, an abdominoperineal resection was not performed.
Positron emission tomography–based imaging verified no evidence of further metastases, and a
subsequent bone marrow (BM) biopsy showed 55% blasts in line with a concomitant progression of
MDS to secondary AML (FAB M1) and aggravation of thrombocytopenia (Figure 1B). Furthermore,
IDH1, IDH2, ASXL1, RUNX1, and STAG2 mutations were still present (Figure 1A). The patient
accepted the recommended application of PEM, but he declined locoregional radiotherapy.
According to the patient’s preference, secondary AML was considered to be treated with
supportive care only.
Methods
Clinical and molecular response assessment
The patient was seen in the outpatient department for blood checks every week while BM diagnostics
including metaphase cytogenetics and molecular analysis were carried out every 2 to 3 months
according to standard methods.7,8 PEM was administered according to guidelines for patients with
unresectable melanoma at a dose of 2 mg/kg IV over 30 minutes every 3 weeks.
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Immune monitoring
Immune profiling was performed in the blood (every 4 weeks) and
BM (every 2-3 months) of the patient during therapy. Peripheral
blood (PB) and BM were prepared by Ficoll-Hypaque density
centrifugation and used for immunofluorescence staining. The
phenotype of T cells and AML cells, as well as the frequency of
regulatory T cells and myeloid-derived suppressor cells, was
determined by using fluorochrome-labeled antibodies (supple-
mental Table 1) and analyzed by flow cytometry. Furthermore, the
presence of T cells was explored in BM (immunohistochemistry,
cytomorphology) and melanoma (immunohistochemistry).
Results and discussion
After 2 months of single-agent PEM treatment, platelet count
increased from 34 Gpt/L to 81 Gpt/L in line with a response
according to International Working Group criteria9 (Figure 1B).
During the course of PEM treatment, neutropenia persisted
ranging from 0.68 to 0.96 Gpt/L, and blasts in the BM remained
between 60% and 80%. Because of chronic anemia, the patient
required red blood cell (RBC) transfusions every 4 weeks during
the first months of therapy. The clinical course was complicated
by a PEM-induced pneumonitis at ;5 months after start of
therapy, necessitating corticosteroid treatment and an 8-week
rest period of PEM. During drug holiday, the patient lost his
platelet response, and RBC transfusion frequency increased up
to every 2 weeks. After restarting therapy, platelet response was
regained (Figure 1B), and RBC transfusion frequency could be
extended again to every 4 weeks. Regarding the melanoma, the
patient achieved stable disease throughout the observation
period.
When investigating the PD-L1 expression or mutational load of
tumor tissues and the frequency and phenotype of immune cells
in tumor patients prior to PD-1 inhibitor therapy, several potential
biomarkers have been described.10 Such studies help to select
treatment responders, to discover mechanisms underlying anti-
PD-1 therapy, and to identify modes of treatment resistance.
Thus, it has been shown that PD-L1 expression in tumor tissues is
associated with clinical responses in anti-PD-1 antibody-treated
patients.11 However, other clinical trials yielded contradictory
results.11 Here, we found that PD-L1 is not detectable on AML
blasts in PB and BM (Figure 2A-B; supplemental Figure 1) before
PEM treatment. However, a significant proportion of AML blasts
increased PD-L1 expression thereafter, which was accompanied
by a significant improvement of platelet count. PD-L1 expression
on blasts in PB reached a maximum of 72%, which was reversible
during treatment interruption. After restarting therapy, the
percentage of PD-L1 expression on AML blasts in PB increased
again and remained stably high with continuous therapy. This
pattern is a hint for the direct linkage between PEM treatment and
upregulation of PD-L1 expression on target cells induced by
effective immunotherapy.12
So far, only limited clinical data are available on the pattern of
PD-L1 or PD-1 expression on T cells in patients with myeloid
disease.13 We found that PD-L1 and PD-1 expression also
increased on PB- and BM-derived T cells during PEM therapy
(Figure 2C-F; supplemental Figure 1). The direct relationship of
these findings to PEM therapy is supported by the observation
that T cells also showed a marked reduction of PD-L1 and PD-1
expression in PB during treatment interruption. The percentage of
PD-L1- or PD-1-expressing CD41 and CD81 T cells in PB
increased again after restarting PEM treatment, indicating that
these effects are a direct result of PD-1 blockade. When
exploring the frequency of regulatory T cells and myeloid-
derived suppressor cells in BM and PB before and during PEM
therapy, we did not observe marked changes (supplemental
Figure 2A-D).
A recent study revealed that preexisting intratumoral CD81
T cells may predict clinical response to anti-PD-1 therapy.14 In
our case, frequency of BM-infiltrating T cells was within the
normal range (7% of BM nucleated cells)15 (supplemental
Figure 3A). Furthermore, only a few scattered T cells were
detectable in melanoma tissues prior to therapy (supplemental
Figure 3B).
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Figure 1. Variant allele frequency of mutations and course of platelet count
prior to and during PEM therapy. (A) Variant allele frequency of single-nucleotide
variants detected in IDH1, IDH2, ASXL1, RUNX1, and STAG2 in the patient before
and during treatment with PEM. Analyses were done using published methods (panel
next-generation sequencing analysis for 54 mutations; Trusight Myeloid Panel) including
targeted ultradeep analysis for IDH1 and IDH2 with a sensitivity down to 0.1%.19 (B)
After diagnosis of MDS EB-1, the patient presented with persistent thrombocytopenia.
Two months after PEM treatment initiation, platelet counts increased from 34 Gpt/L
to 81 Gpt/L. The course was complicated by a PEM-associated pneumonitis at
;5 months after the start of therapy. During this period, PEM was stopped for
8 weeks, and the patient lost his platelet response subsequently. Response was
regained after reintroduction of therapy. sAML, secondary AML.
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Moreover, a higher mutation burden resulting in a higher number of
tumor-derived neoantigens has been linked to better response to
immune therapy.16 The number of mutations in our patient is in line
with previous data, indicating that AML secondary to MDS displays
a median of 4 mutations compared with 2 in de novo cases.17
During the 14 months of PEM treatment, AML staging showed no
signs of progressive disease including stable blast cell number in
the BM. Notably, preexisting IDH1 mutation completely disap-
peared, whereas IDH2, ASXL1, RUNX1, and STAG2 mutations
persisted (Figure 1A).
Median survival of elderly AML patients is ,1 year with first-line
hypomethylating agents.18 To our knowledge, this is the first case
report describing the clinical course of a patient with AML during
single-agent first-line therapy with PEM. PD-1 inhibition was
accompanied by a significant platelet response and upregula-
tion of PD-1 and PD-L1, whereas IDH1 mutation completely
disappeared. Our findings, therefore, indicate that single-agent
therapy with PEM might display disease-modifying activity in a
subset of AML patients.
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Figure 2. Expression of PD-L1 and PD-1 on AML blasts
and T cells prior to and during PEM therapy. PB- and
BM-derived AML blasts (A-B) and T cells (C-F) were stained
with fluorochrome-conjugated antibodies and analyzed by flow
cytometry prior to and at various time points during PEM
treatment. Blasts were defined as CD45low cells and stained
for PD-L1 expression. Furthermore, T cells were characterized
as CD451, CD31, and CD41 or CD81 populations. CD81
T cells (C-D) and CD41 T cells (E-F) were analyzed for their
expression of PD-1 and PD-L1. Values in the graphs represent
the percentage of cells staining positive for each molecule at
indicated different time points.
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